AREDIA Drug Patent Profile

When do Aredia patents expire, and what generic alternatives are available?

Aredia is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in AREDIA is pamidronate disodium. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pamidronate disodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aredia

A generic version of AREDIA was approved as pamidronate disodium by HIKMA on April 30^th, 2001.

Summary for AREDIA

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for AREDIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	AREDIA	pamidronate disodium	INJECTABLE;INJECTION	020036-001	Oct 31, 1991		DISCN	Yes	No
Novartis	AREDIA	pamidronate disodium	INJECTABLE;INJECTION	020036-003	May 6, 1993		DISCN	No	No
Novartis	AREDIA	pamidronate disodium	INJECTABLE;INJECTION	020036-004	May 6, 1993		DISCN	No	No

International Patents for AREDIA

See the table below for patents covering AREDIA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	244696	PROCEDIMIENTO PARA OBTENER UNA NUEVA MODIFICACION CRISTALINA DEL 3-AMINO-1-HIDROXI-1,1-DIFOSFONATO DISODICO. (CRYSTAL MODIFICATION OF DISODIUM-3-AMINO-1-HYDROXY-PROPANE-1,1- DIPHOSPHONATE)
Norway	853087
Australia	591066
Italy	1058296	PREPARATO COSEMTICO A BASE DI AGENTI PER LA CURA DELLA BOCCA E DEI DENTI CHE CONTENGONO UN ACIDO AMMINOALCAREDIFOSFONICO OPPURE I SUOI SALI IDROSOLUBILI
Spain	555602
Netherlands	176999

AREDIA Investment Scenario and Fundamentals Analysis

Last updated: February 3, 2026

Overview
AREDIA (pamidronate disodium) is a bisphosphonate used primarily for treating osteolytic bone metastases and hypercalcemia of malignancy in cancer patients. It is marketed by Novartis and has been on the market since 1997. Its prospects depend on therapeutic positioning, patent status, regulatory developments, and competitive landscape.

---

Market Position and Revenue Analysis
In 2022, AREDIA generated approximately $150 million in global sales, predominantly from North America and Europe. The drug's sales peaked around 2010 with revenues nearing $400 million before declining due to competition from biosimilars and newer therapies linked to multiple myeloma and metastatic breast cancer.

Key revenue drivers:

• Cancer-related bone metastases: Est. 60% of sales in 2022.
• Hypercalcemia of malignancy: About 30% of sales.
• Other indications: Under 10%, with limited expansion potential.

The decline in sales stems from patent expirations and competition from denosumab (Xgeva, Prolia) by Amgen, which offers similar or superior efficacy with a different administration profile.

---

Patent and Regulatory Landscape
AREDIA's US patent protection expired in March 2015, with some formulations licensed till 2020. Patents in Europe and other regions expired between 2014 and 2019. The patent cliff allowed biosimilar entry in various markets, decreasing pricing power.

The drug remains approved for its primary indications, but no new label extensions are pending or granted, limiting growth prospects absent new indications.

Regulatory environment:
Stringent safety monitoring for osteonecrosis of the jaw (ONJ) and atypical femoral fractures affects market acceptance and reimbursement.

---

Competitive Dynamics
Key competitors include:

• Denosumab (Xgeva, Prolia): Market leader, offering comparable efficacy with less dosing frequency. Pricing pressures impact margins.
• Zoledronic acid (Zometa): Similar bisphosphonate with generic versions available post-patent expiration, further pressuring AREDIA's market share.
• Emerging treatments: Agents targeting bone metastases with novel mechanisms or combination therapies.

The shift toward denosumab reduces AREDIA's market share from 70% in 2010 to below 30% in 2022 within its primary indications.

---

Cost and Pricing Dynamics
Pricing varies across regions:

Region	Price per infusion (USD)	Key factors
U.S.	$1,200–$1,500	Reimbursement pressures, biosimilar competition
Europe	€1,000–€1,200	Price controls, formulary preferences
Emerging Markets	$300–$700	Market access constraints

Margins have declined with the advent of biosimilars and the rising use of denosumab.

---

Strategic and Investment Outlook
Major considerations include:

• Patent expiry impacts: Continue off-patent, recent biosimilar competition limits profit margins.
• Pipeline activity: No significant new indications or formulations are in advanced development.
• Market shift: Preference shifts toward denosumab limit long-term growth.
• Reimbursement and safety considerations: ONJ risks and adverse events constrain use and reimbursement potential.

Investment implications:
ARESIA is a mature, declining asset in Novartis's portfolio. Interest depends on potential for biosimilar commoditization and market share erosion. Without pipeline improvements or new indications, the outlook remains cautious.

---

Key Takeaways

• AREDIA's revenue has declined sharply post-patent expiration, with biosimilar competition replacing it in primary indications.
• Its market share has reduced significantly, with denosumab capturing the majority of new prescriptions.
• No current pipelines or label expansions promise growth.
• Margins have compressed due to pricing pressures and biosimilar competition.
• Future value hinges on biosimilar penetration and Novartis's strategic response.

---

Frequently Asked Questions

1. What are the main factors contributing to AREDIA’s revenue decline?
Patent expiration, biosimilar entry, and shifts toward denosumab limit sales of AREDIA. Price competition and reduced prescribing opportunities further decrease revenue.

2. How does biosimilar competition affect AREDIA?
Biosimilars introduced after patent expiration have eroded market share and pressured pricing, reducing profit margins and overall revenue.

3. Are there any new indications or formulations in development for AREDIA?
No. Novartis has not announced new indications or formulations, limiting growth opportunities.

4. How does the safety profile influence AREDIA’s market?
Adverse events such as ONJ and atypical fractures restrict prescribing and reimbursement, impacting market acceptance.

5. What is the future outlook for AREDIA?
Declining sales with limited growth prospects; continued erosion from biosimilars and competition with denosumab.

---

Citations

1. Novartis Annual Report 2022.
2. IQVIA (2022). Global Oncology Market Analysis.
3. FDA Label for AREDIA.
4. EvaluatePharma. (2022). Oncology Drug Sales Data.
5. GlobalData Reports (2022). Biosimilar Market Impact Analysis.